Table. Baseline Clinical and CMR Measurements.
| Variable | No. (%) | |||
|---|---|---|---|---|
| All Patients | CMR Patients | |||
| With No CMR (n = 660) |
With CMR (n = 340) |
With CABG Only (n = 177) |
With CABG Plus SVR (n = 163) |
|
| Age, mean (SD), y | 62.0 (9.6) | 60.9 (9.8) | 61.3 (9.9) | 60.4 (9.7) |
| Women | 100 (15.2) | 47 (13.8) | 24 (13.6) | 23 (14.1) |
| Hypertension | 384 (58.6) | 198 (58.2) | 101 (57.1) | 97 (59.5) |
| Diabetes | 230 (34.8) | 114 (33.5) | 57 (32.2) | 57 (35.0) |
| Stroke | 39 (5.9) | 17 (5.0) | 8 (4.5) | 9 (5.5) |
| Peripheral vascular disease | 106 (16.1) | 40 (11.8) | 26 (14.7) | 14 (8.6) |
| Renal insufficiency | 62 (9.4) | 23 (6.8) | 10 (5.6) | 13 (8.0) |
| Atrial fibrillation | 82 (12.4) | 35 (10.3) | 18 (10.2) | 17 (10.4) |
| Heart rate, mean (SD), bpm | 67 (12) | 70 (13) | 70 (14) | 70 (12) |
| Blood pressure, mean (SD), mm Hg | ||||
| Systolic | 121 (17) | 120 (18) | 121 (18) | 120 (18) |
| Diastolic | 73 (12) | 74 (11) | 74 (10) | 75 (11) |
| LV ejection fraction, mean (SD), % | NA | 28 (11) | 28 (11) | 27 (12) |
| LV, mean (SD), mL/m2 | ||||
| End-diastolic volume index | NA | 108 (39) | 106 (36) | 112 (42) |
| End-systolic volume index | NA | 80 (36) | 77 (33) | 83 (39) |
| Aspirin use | 488 (74) | 278 (82) | 143 (81) | 135 (84) |
| Angiotensin-converting enzyme inhibitors | 574 (87) | 302 (89) | 159 (90) | 143 (88) |
| Statin use | 502 (76) | 270 (79) | 140 (79) | 130 (80) |
| β-Blocker use | 548 (83) | 308 (91) | 159 (90) | 149 (91) |
| ICD use | ||||
| At baseline | 33 (5.0) | 1 (0.3) | 1 (0.6) | 0 (0) |
| During follow-up | 114 (17.3) | 72 (21.2) | 41 (23.2) | 31 (19.0) |
Abbreviations: bpm, beats per minute; CABG, coronary artery bypass grafting; CMR, cardiovascular magnetic resonance; ICD, implantable cardioverter defibrillator; LV, left ventricular; NA, not applicable; SVR, surgical ventricular reconstruction.